Roger Zheng

2018 - Now Associate Consultant, IQVIA, Shanghai Job description: Proposal writing, desk research, project management, physician interview, data analysis, report delivery Core member for 9 projects including cancer, neuro disorder and supplies areas, besides involved in more than 10+ projects; total volume is more than 6m RMB. Market Understanding Endo-surgery stapler line buttress market opportunity • Estimated the clinical evaluation and current market coverage and usage of existing buttress products to help decide the value of acquiring potential target • Explored the unmet needs for surgeons using stapler line and tested the acceptance of new product • Suggested GI surgery as the most potential department and designed messages for new product Launch Strategy Development Product positioning, physician segmentation and messaging of PD-1 product • Understood the competitive landscape, physician’s mindset and perception of current IO products • Built physician segmentation and defined the profiles which have been recognised by global team • Designed and tested the message bundles of PD-1 product and set the KPI baseline for this product Formulation Update Anti-HER2 portfolio launch planning strategy • Explored the market potential of trastuzumab SC and anti-HER2 FDC SC to defend biosimilars • Tested the pricing sensitivity of SC and acceptance of improving turn-over rate by using SC • Found the main stakeholders in the hospital listing and the challenges for SC products market entry Pipeline Expansion AED family pre-launch KPI setting and performance management • Assessed the total AED IV market and the opportunities of LEV IV in neuro surgery • Understood the gap between lacosamide strategy and physician’s usage and attitudes • Provided deep epilepsy market insights that AEDs with better safety were using in the first line

Final project: Role of activity-dependent neuroprotective protein in telomere maintenance in cervical cancer and osteosarcoma cells

Final Project: Gene expression of GREB1 and PLK1 under estrogen responses with/without drugs in estrogen receptor mutated breast cancer cells